Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Down 11.0 %

Shares of Oragenics stock opened at $0.33 on Tuesday. Oragenics has a twelve month low of $0.25 and a twelve month high of $6.42. The company’s 50 day moving average is $0.34 and its 200 day moving average is $0.65. The company has a market cap of $4.07 million, a price-to-earnings ratio of -0.05 and a beta of 0.40.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.